Evidence map›Paper›PMID 41828443›Full record

ArticleInternational journal of molecular sciences2026

Reactive Stroma as a Transversal Prognostic Biomarker for Metastasis in Breast Cancer: Integration of Digital Histopathology and Transcriptomic Profiling.

Daniela P Barrera, Muriel A Núñez, Valentina Cerda I, J Sebastián Contreras-Riquelme, Jenny Henríquez, Guillermo Carrasco, Alejandra Pereira, Vania Figueroa, Verónica Toledo, Badir Chahuan and 9 more

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Daniela P BarreraEnviron, Startup and Spin-Off from Pontificia Universidad Católica de Chile, Santiago 7500571, Chile.ORCID 0009-0002-8546-5941
Muriel A NúñezEnviron, Startup and Spin-Off from Pontificia Universidad Católica de Chile, Santiago 7500571, Chile.
Valentina Cerda IEnviron, Startup and Spin-Off from Pontificia Universidad Católica de Chile, Santiago 7500571, Chile.
J Sebastián Contreras-RiquelmeEnviron, Startup and Spin-Off from Pontificia Universidad Católica de Chile, Santiago 7500571, Chile.
Jenny HenríquezEnviron, Startup and Spin-Off from Pontificia Universidad Católica de Chile, Santiago 7500571, Chile.
Guillermo CarrascoEnviron, Startup and Spin-Off from Pontificia Universidad Católica de Chile, Santiago 7500571, Chile.
Alejandra PereiraEnviron, Startup and Spin-Off from Pontificia Universidad Católica de Chile, Santiago 7500571, Chile.
Vania FigueroaEnviron, Startup and Spin-Off from Pontificia Universidad Católica de Chile, Santiago 7500571, Chile.
Verónica ToledoUnidad Cirugía Oncológica Mamaria, OECI Cancer Center, Fundación Arturo López Pérez, Santiago 7500921, Chile.
Badir ChahuanUnidad Cirugía Oncológica Mamaria, OECI Cancer Center, Fundación Arturo López Pérez, Santiago 7500921, Chile.
Jorge Sapunar-ZentenoCentro de Investigación e Innovación en Cáncer, OECI Cancer Center, Fundación Arturo López Pérez, Santiago 7500921, Chile.
Ximena RodríguezHospital San José, Santiago 8380419, Chile.
Daniel MorenoFacultad de Medicina, Pontificia Universidad Católica de Chile, Santiago 8331150, Chile.
José Tomás LarachFacultad de Medicina, Pontificia Universidad Católica de Chile, Santiago 8331150, Chile.
Benjamín PrietoEnviron, Startup and Spin-Off from Pontificia Universidad Católica de Chile, Santiago 7500571, Chile.
Patricia GarcíaEnviron, Startup and Spin-Off from Pontificia Universidad Católica de Chile, Santiago 7500571, Chile.
Leonor MoyanoInstituto Nacional del Cáncer, Santiago 8380450, Chile.
José PeñaFacultad de Medicina, Pontificia Universidad Católica de Chile, Santiago 8331150, Chile.
Javier Cerda-InfanteEnviron, Startup and Spin-Off from Pontificia Universidad Católica de Chile, Santiago 7500571, Chile.

Funding

Corporación de Fomento de la Producción 22CVC2-218129Production Development Corporation 20IAT130292Production Development Corporation 22CVID-206707
6 · The paper itself

Abstract

Distant metastasis is the main cause of breast cancer (BC) mortality, yet current prognostic models remain largely tumor-centric and underutilize stromal biology. In this study, we quantified reactive stroma, a collagen-rich and fibrotic fraction of the stromal compartment, as a subtype-independent biomarker of metastatic risk. A retrospective cohort of 182 FFPE primary BC biopsies (2006-2020) was analyzed. Total stroma was quantified on H&E-stained sections and reactive stroma on Masson's trichrome using QuPath with pathologist validation. Cutoffs were defined using maximally selected rank statistics, and overall survival (OS) and metastasis-free survival (MFS) were evaluated by Kaplan-Meier analysis and multivariable Cox regression. RNA sequencing was performed in a subset of cases to characterize associated transcriptomic programs. While total stromal content showed univariate associations with OS and MFS, it was not independently prognostic after adjustment. In contrast, high reactive stroma (cutoff 53.2%) independently predicted shorter MFS (HR = 3.76;

Indexed as

Biomarkers, TumorBreast NeoplasmsStromal CellsTranscriptomeFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMiddle AgedNeoplasm MetastasisPrognosisRetrospective StudiesTumor MicroenvironmentBiomarkers, Tumorcancer prognosisdigital pathologymetastasisreactive stromatumor microenvironment

Identifiers

PMID41828443
PMCPMC12984561

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.